• Title/Summary/Keyword: 대한방사선종양학회

Search Result 2,500, Processing Time 0.038 seconds

Nonfunctional Parathyroid Carcinoma: A Case Report (비기능성 부갑상선암: 증례 보고)

  • Choi, Sang-Gyu
    • Radiation Oncology Journal
    • /
    • v.28 no.2
    • /
    • pp.111-116
    • /
    • 2010
  • Parathyroid carcinoma is a rare endocrine malignancy accounting for 0.5% to 4.0% of all cases of hyperparathyroidism and commonly present as hypercalcemia and parathyroid hormone (PTH) elevation. Nonfunctional parathyroid carcinoma does not show symptoms of hyperparathyroidism and only showed a vague indication of being pathologic, even when detected late. The optimal treatment is en bloc resection of the cancer, but frequent local recurrence after surgery has been reported. Adjuvant local treatment such as radiotherapy may improve the likelihood local control in cases with incompletely resected or microscopic residual tumor. The results of this study point to a case of nonfunctional parathyroid carcinoma treated by external beam radiotherapy after en-bloc resection of cancer.

Angiosarcoma of the Scalp : A Case Report and the Radiotherapy Technique (두피에 발생한 혈관육종 : 증례보고와 방사선치료방법에 대한 고찰)

  • Kim, Joo-Young;Choi, Jin-Ho
    • Radiation Oncology Journal
    • /
    • v.16 no.3
    • /
    • pp.351-355
    • /
    • 1998
  • Cutaneous angiosarcomas are uncommon malignancies which account about 1$\%$ of sarcomas. They are found most commonly in the head and neck regions, frequently on the scalp. Although preferred treatment has been combined surgery and postoperative radiation therapy, the extensiveness and multiplicity of the lesions set limits to such an approach and the patient is often referred for radiotherapy without surgery. As the entire scalp usually needs to be treated, radiation therapy is a challenging problem to radiation oncology staffs. We report a case of angiosarcoma of the scalp, which was treated successfully by radiation therapy with a simple and repeatable method using mixed Photon and electron beam technique. Using a bolus to increase the surface dose of the scalp and to minimize dose to the normal tissues of the brain desirable but difficult technically to be well conformed to the three dimensional curved surface such as vertex of the head. A helmet made of thermoplastics filled with paraffin was elaborated and used for the treatment, resulting of the relatively uniform surface doses along the several points measured on the scalp, the difference among the points not exceeding 7$\%$ of the prescribed dose by TLD readings.

  • PDF

A Comparative Evaluation of Dosal Usefulness in Total Scalp Irradiation according to Treatment Plans and Methods (총 두피 방사선치료 시 치료계획 방법에 따른 선량적 유용성 비교 평가)

  • Park byeal nim;Jung dong min;Kwon yong jae;Cho yong wan;Kim se young;Park kwang soon;Park ryeong hwang;Baek jong geol
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.34
    • /
    • pp.43-50
    • /
    • 2022
  • Objective: The purpose of this study is to choose a treatment plan and equipment to maximize tangential irradiation to protect the normal brain tissues as much as possible during total scalp irradiation. Subjects and Methods: After zoning the total scalp of a phantom and selecting a target area for treatment, the study made a Helical TomoTherapy(HT) plan, a Helical TomoTherapy with a Complete Block(HTCB) plan, and a Volumetric Modulated Arc Therapy(VMAT) plan. All of these plans made sure that the volume of a treatment plan with 95% of a prescription dose(40 Gy) would not exceed 95% of the entire volume and that Dmax would not be more than 110% of the prescription dose. The therapy plans compared doses among organs at risk of damage including the brain. Doses in the brain tissues were assessed based on the volumetric criteria for normal tissues in Emami et al. Results: HT, HTCB, and VMAT had a dose of 21.68 Gy, 13.75 Gy, and 20.89 Gy, respectively, in brain tissues at D33%, a dose of 7.06 Gy, 3.21 Gy, and 7.84 Gy, respectively, at D67%, and a dose of 3.14 Gy, 1.75 Gy, and 3.84 Gy, respectively, at D100%. They recorded a Dmean of 16.64 Gy, 11.78 Gy, and 16.64 Gy, respectively. These results show that the overall dose was low in the HTCB plan. When the volume of a low dose was calculated based on 5 Gy, they recorded 87%, 49%, and 96%, respectively, in V5Gy. In addition, the maximum dose in the remaining organ(brain stem, hippocampus, and both lenses) except for the optic pathway was the lowest in HTCB Conclusion: The findings demonstrate that TomoTherapy with a complete block minimized a dose in organs at risk of damage including the brain and hippocampus on both sides and accordingly reduced the probability of side effects such as radiation-induced brain injuries and a resulting decrease in neurocognitive functions. In addition to total scalp irradiation, if additional studies on ring targets treated in various areas are conducted to establish the benefits of tangential irradiation, it is believed that TomoTherapy using Complete Block can be used to maximize tangential irradiation in treatment planning.

EVALUATION OF THE DIAGNOSTIC IMAGING OF THE MALIGNANT TUMORS IN THE ORAL AND MAXILLOFACIAL REGION : COMPARISON OF CONVENTIONAL RADIOGRAMS AND MRI (구강영역 악성종양의 영상진단학적 평가 : 방사선사진과 자기공명영상소견의 비교)

  • Lee Young-Mi;Park Tae-Won
    • Journal of Korean Academy of Oral and Maxillofacial Radiology
    • /
    • v.23 no.2
    • /
    • pp.323-332
    • /
    • 1993
  • 저자는 1988년 6월 1일부터 1993년 6월 30일까지 서울대학교병원 치과진료부에 내원하여, 병리조직학적으로 확인된 구강악안면부 악성종양환자 35명의 방사선사진 소견과 자기공명영상 소견을 비교하여 다음과 같은 결론을 얻었다. 1. 일반적인 방사선사진소견으로는 미만성의 골파괴가 15례 (42.9%), 연조직종괴의 음영이 7례 (20,0%), 부유치를 보인 경우가 3례 (8.6%), 골경화가 2례 (51.7%)로 나타났다. 2. 자기공명영상 소견은 연조직종괴가 23례 (65.7%), 골수침범이 12례(34.5%), 피질골 파괴가 14례(40.0%), 정상피질골에 골수침범이 1례 (2.9%), 지방층소실이 19례(54.3%), 림파절전이가 8례 (22.9%), 조영증강이 15례 (42.9%), 골증식이 1례 (2.9%)였다. 3. 구강악안면부의 악성종양환자에 있어서, 방사선사진에서 관찰하기 힘들었던, 종양의 구강저, 저작근, 부인두강, 사골동, 측두하와, 악하선, 비강 등 인접조직으로의 침범여부 및 골파괴 정도와 림파절전이를 평가하는 데 자기공명영상은 도움을 주었다. 4. 정진율은, 방사선사진에서 35례중 16례로 45.7%였고, 자기공명영상에서는 35례중 27례로 77.1%로 자기공명영상의 정진율이 더 높았으나, 일반적인 방사선사진이 자기공명영상보다 더 우세한 경우도 2례 있었다.

  • PDF

Radiotherapy in Supraglottic Carcinoma - With Respect to Locoregional Control and Survival - (성문상부암의 방사선치료 -국소종양 제어율과 생존율을 중심으로-)

  • Nam Taek-Keun;Chung Woong-Ki;Cho Jae-Shik;Ahn Sung-Ja;Nah Byung-Sik;Oh Yoon-Kyeong
    • Radiation Oncology Journal
    • /
    • v.20 no.2
    • /
    • pp.108-115
    • /
    • 2002
  • Purpose : A retrospective study was undertaken to determine the role of conventional radiotherapy with or without surgery for treating a supraglottic carcinoma in terms of the local control and survival. Materials and Methods : From Jan. 1986 to Oct. 1996, a total of 134 patients were treated for a supraglottic carcinoma by radiotherapy with or without surgery. Of them, 117 patients who had completed the radiotherapy formed the base of this study. The patients were redistributed according to the revised AJCC staging system (1997). The number of patients of stage I, II, III, IVA, IVB were $6\;(5\%),\;16\;(14\%),\;53\;(45\%),\;32\;(27\%),\;10\;(9\%)$, respectively. Eighty patients were treated by radical radiotherapy in the range of $61.2\~79.2\;Gy$ (mean : 69.2 Gy) to the primary tumor and $45.0\~93.6\;Gy$ (mean : 54.0 Gy) to regional lymphatics. All patients with stage I and IVB were treated by radiotherapy alone. Thirty-seven patients underwent surgery plus postoperative radiotherapy in the range of $45.0\~68.4\;Gy$ (mean : 56.1 Gy) to the primary tumor bed and $45.0\~59.4\;Gy$ (mean : 47.2 Gy) to the regional lymphatics. Of them, 33 patients received a total laryngectomy (${\pm}lymph$ node dissection), three had a supraglottic horizontal laryngectomy (${\pm}lymph$ node dissection), and one had a primary excision alone. Results : The 5-year survival rate (5YSR) of all patients was $43\%$. The 5YSRs of the patients with stage I+II, III+IV were $49.9\%,\;41.2\%$, respectively (p=0.27). However, the disease-specific survival rate of the patients with stage I (n=6) was $100\%$. The 5YSRs of patients who underwent surgery plus radiotherapy (S+RT) vs radiotherapy alone (RT) in stage II, III, IVA were $100\%\;vs\;43\%$ (p=0.17), $62\%\;vs\;52\%$ (p=0.32), $58\%\;vs\;6\%$ (p<0.001), respectively. The 5-year actuarial locoregional control rate (5YLCR) of all the patients was $57\%$. The 5YLCR of the patients with stage I, II, III, IVA, IVB was $100\%,\;74\%,\;60\%,\;44\%,\;30\%$, respectively (p=0.008). The 5YLCR of the patients with S+RT vs RT in stage II, III, IVA was $100\%\;vs\;68\%$ (p=0.29), $67\%\;vs\;55\%$ (p=0.23), $81\%\;vs\;20\%$ (p<0.001), respectively. In the radiotherapy alone group, the 5YLCR of the patients with a complete, partial, and minimal response were $76\%,\;20\%,\;0\%$, respectively (p<0.001). In all patients, multivariate analysis showed that the N-stage, surgery or not, and age were significant factors affecting the survival rate and that the N-stage, surgery or not, and the ECOG performance index were significant factors affecting the locoregional control. In the radiotherapy alone group, multivariate analysis showed that the radiation response and N-stage were significant factors affecting the overall survival rate as well as locoregional control. Conclusion : In early stage supraglottic carcinoma, conventional radiotherapy alone is an equally effective modality compared to surgery plus radiotherapy and could preserve the laryngeal function. However, in the advanced stages, radiotherapy combined with concurrent chemotherapy for laryngeal preservation or surgery should be considered. In bulky neck disease, all the possible planned neck dissections after induction chemotherapy or before radiotherapy should be attempted.

A study on the manufacturing method and usefulness of Bolus-helmet used for malignant scalp tumor patients (악성두피종양환자에게 사용되는 보루스헬멧(Bolus-helmet)의 제작방법 및 유용성에 관한 연구)

  • Lee, joung jin;Moon, jae hee;Kim, hee sung;Kim, koon joo;Seo, jung min;Choi, jae hoon;Kim, sung gi;Jang, in gi
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.33
    • /
    • pp.15-24
    • /
    • 2021
  • This study is about the introduction and usefulness evaluation of the manufacturing method of the bolus-helmet. Helmet-production for the treatment of scalp tumor patients has been tried and will continue in many creative and various ways. However, Most of the research data did not significantly reduce the psychological burden and physical and physical discomfort that the patient had to bear due to the time and economic cost required for the production of the helmet, the convenience of production, and the complexity of the process. In addition, recently, studies using more advanced technologies and equipment such as 3D-printer technology, which are being studied as a way to increase the treatment effect, are being introduced, but the time, economic cost, and psychological and physical burden are still the sole responsibility of the patient. Isn't it getting worse? The reality is that the thoughts of concern cannot be erased. Therefore, by maintaining the physical properties of the bolus and manufacturing a helmet without incurring additional costs, the physical and physical discomfort aggravated to the patient was reduced and the procedure and time for helmet manufacturing were minimized. In this way, it was possible to reduce the time, economic cost, and physical discomfort required for the production of the helmet, and it was also possible to minimize the psychological burden of the patient, although it is invisible. Additionally, in evaluating the usefulness of helmets, we are able to continuously seek and develop ways to reduce the air-gap interval, and as a result, we will be able to introduce a method to keep it within 2.0mm along with the manufacturing method through this study. I feel very welcome. Finally, I hope that anyone working in the Department of Radiation Oncology will be able to easily manufacture the helmet required for radiation therapy using a bolus through the guide-line on helmet manufacturing provided by this institute. I hope and hope that if you have any questions or inquiries that arise during the production process, please feel free to contact us through the researcher's e-mail or mobile phone at any time.